title: Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma.
abstract: OBJECTIVE
  To determine whether interferon alfa-2b (IFN-alfa; intron-A, Schering Corp, Kenilworth, NJ) can induce a remission in patients previously treated with active specific immunotherapy (therapeutic melanoma vaccine) without response.
  
  
  METHODS
  Eighteen patients with disseminated melanoma who had failed to respond to at least five injections of Melacine therapeutic melanoma vaccine (Ribi ImmunoChem Research, Inc, Hamilton, MT) were then treated IFN-alfa after a 4-week interval. IFN-alfa 5 or 6 x 10(6) U/m2 was self-administered three times a week subcutaneously by melanoma patients for at least 2 months. Computed tomographic (CT) scans of the chest, abdomen, and pelvis and magnetic resonance imaging of the brain were performed within 4 weeks before treatment as a baseline, and then at 2-month intervals during treatment to evaluate response. All 18 patients were HLA-typed before treatment. The frequency of cytolytic T-cell precursors (pCTL) in the blood had been measured weekly in 13 of the patients during treatment with Melacine.
  
  
  RESULTS
  Eight of 18 patients (44.4%) had a major objective clinical response induced by IFN-alfa, including site-specific complete remissions in five. Responses lasted a median of 11 months. The median survival duration of the responders has not been reached, and exceeds 32 months. The group as a whole had a median survival duration of 10.1 months, and nonresponders lived 7.3 months. Cytolytic T-cell precursors had been increased by immunization in all five responding patients tested, but also in five of eight nonresponders. There was no association of response to IFN-alfa with specific HLA phenotypes, in contrast to our previous results with melanoma theraccine alone.
  
  
  CONCLUSIONS
  These data suggest an additive effect of active specific immunotherapy and IFN-alfa on the objective response rate, perhaps through upregulation of HLA molecules and tumor-associated antigens on the tumor cell by IFN-alfa, after immunization of the patient by Melacine. This treatment may have improved survival over that expected in metastatic melanoma.
authors.affiliation: Department of Medicine, Norris Comprehensive Cancer Center, University of South California School of Medicine, Los Angeles 90033.
authors.forename: M S
authors.initials: MS
authors.lastname: Mitchell
authors.forename: J
authors.initials: J
authors.lastname: Jakowatz
authors.forename: W
authors.initials: W
authors.lastname: Harel
authors.forename: G
authors.initials: G
authors.lastname: Dean
authors.forename: L
authors.initials: L
authors.lastname: Stevenson
authors.forename: W D
authors.initials: WD
authors.lastname: Boswell
authors.forename: S
authors.initials: S
authors.lastname: Groshen
mesh_terms: D000328:Adult; D000368:Aged; D019496:Cancer Vaccines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008545:Melanoma / Q000000981:diagnostic imaging / Q000556:secondary / Q000628:therapy*; D008875:Middle Aged; D011994:Recombinant Proteins; D012074:Remission Induction; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D019496:Cancer Vaccines; D000077190:Interferon alpha-2; D016898:Interferon-alpha; C116434:Melacine; D011994:Recombinant Proteins